NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough

Kohei Omachi, Hirofumi Kai, Michel Roberge, Jeffrey H. Miner
minerj@wustl.edu

Highlights
NanoLuc fusion constructs identified COL4A5 mutants susceptible to PTC readthrough
Readthrough enhancer and “designer” compounds promoted PTC readthrough
Split-NanoLuc fusion constructs identified functional missense readthrough products
Cultured Col4a5 nonsense mutant mouse kidney cells were susceptible to readthrough

Omachi et al., iScience 25, 103891
March 18, 2022 © 2022 The Author(s).
https://doi.org/10.1016/j.isci.2022.103891
NanoLuc reporters identify COL4A5 nonsense mutations susceptible to drug-induced stop codon readthrough

Kohei Omachi,¹ Hirofumi Kai,² Michel Roberge,³ and Jeffrey H. Miner¹,4,*

SUMMARY

Alport syndrome, a disease of kidney, ear, and eye, is caused by pathogenic variants in the COL4A3, COL4A4, or COL4A5 genes encoding collagen α3α4α5(IV) of basement membranes. Collagen IV chains that are truncated due to nonsense variants/premature termination codons (PTCs) cannot assemble into heterotrimers or incorporate into basement membranes. To investigate the feasibility of PTC readthrough therapy for Alport syndrome, we utilized two NanoLuc reporters in transfected cells: full-length for monitoring translation, and a split version for assessing readthrough product function. Full-length assays of 49 COL4A5 nonsense variants identified eleven as susceptible to PTC readthrough using various readthrough drugs. In split-NanoLuc assays, the predicted missense α5(IV) readthrough products of five nonsense mutations could heterotrimerize with α3(IV) and α4(IV). Readthrough was also observed in kidney cells from an engineered Col4a5 PTC mouse model. These results suggest that readthrough therapy is a feasible approach for a fraction of patients with Alport syndrome.

INTRODUCTION

Alport syndrome is a hereditary kidney glomerular disease with eye and inner ear defects characterized by glomerular basement membrane (GBM) abnormalities leading to progressive glomerulosclerosis and kidney failure (Hudson et al., 2003). Pathogenic variants in either the COL4A3 (Morrison et al., 1991a, 1991b), COL4A4 (Mochizuki et al., 1994) or COL4A5 (Barker et al., 1990) genes encoding the type IV collagen α3, α4, and α5 chains, respectively, cause Alport syndrome. All three chains are necessary to form a functional type IV collagen α3α4α5 network. The chains assemble inside cells into α3α4α5 heterotrimers (protomers), which are secreted into the extracellular space (Gunwar et al., 1998), where they polymerize to build a basement membrane with other components such as laminins, nidogen, and heparan sulfate proteoglycans (Miner, 2011).

The lack or reduction of type IV collagen α3α4α5 in Alport syndrome eventually leads to GBM abnormalities including thinning, thickening, and splitting. Current standard-of-care therapy uses renin-angiotensin system inhibitors such as angiotensin-convertase enzyme inhibitors or angiotensin II receptor blockers. Though they delay progression to kidney failure, they do not cure Alport syndrome (Gross et al., 2003, 2020; Yamamura et al., 2020b). In contrast, development of methods to fix the pathogenic GBM abnormalities compositional, structural, and functional could cure Alport syndrome or overcome the limitations of current treatments.

One of the potential barriers to the treatment of Alport syndrome using a GBM repair approach is the requirement that the abnormal GBM composed of collagen IV α1α1α2 be able to incorporate α3α4α5. Genetic rescue experiments in a Col4a3-null Alport syndrome mouse model has shown that postnatal induction of COL4A3 production in podocytes, the glomerular cells that normally synthesize the collagen IV α3α4α5 network, enables α3α4α5 trimer synthesis, secretion, and incorporation into the Alport GBM, which attenuates loss of kidney function (Lin et al., 2014). This study shows that restoration of the normal type IV collagen α3α4α5 network in the Alport GBM is a feasible approach toward a cure.

In the present study, we focused on chemical-induced restoration of COL4A5 expression in COL4A5 nonsense variant types of Alport syndrome. Nonsense variants resulting in premature termination codons

¹Division of Nephrology, Washington University School of Medicine, 4523 Clayton Avenue, St. Louis, MO 63110, USA
²Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
³Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
⁴Lead contact
*Correspondence: minerj@wustl.edu
https://doi.org/10.1016/j.isci.2022.103891
(PTCs) account for about 6% of Alport syndrome cases (Savige et al., 2016). Type IV collagen chains have a C-terminal NC1 domain that is essential for assembly of heterotrimers inside cells and for network formation in the GBM. Truncated α3, α4, α5 chains without an intact NC1 domain due to PTCs cannot form trimers or polymerize in the GBM (Sundaramoorthy et al., 2002). Therefore, achieving full-length protein expression is a potential therapy for Alport syndrome due to nonsense variants.

Small molecule-based PTC readthrough therapy has been well studied in other genetic diseases such as cystic fibrosis (Crawford et al., 2021; Du et al., 2006), Duchenne muscular dystrophy (Crawford et al., 2020; Kayali et al., 2012), and inherited skin disorders (Lincoln et al., 2018; Woodley et al., 2017). G418, an aminoglycoside class antibiotic, is the most studied drug that induces PTC readthrough. Aminoglycosides bind to prokaryotic ribosomes and inhibit protein synthesis in Gram-negative bacteria. In addition to their affinity for prokaryotic ribosomes, aminoglycosides are known to bind to eukaryotic ribosomes and induce PTC readthrough of nonsense variants by enabling near-cognate aminoacyl-tRNAs to recognize PTCs (Roy et al., 2015). Since the discovery of aminoglycoside-induced PTC readthrough, it has been shown that PTC readthrough can be induced by various aminoglycosides (Du et al., 2006; Friesen et al., 2018; Shulman et al., 2014). Although aminoglycoside-mediated PTC readthrough has the advantages of being well studied and highly efficient, high doses can cause nephrotoxicity and ototoxicity. To overcome these limitations, structurally designed aminoglycosides with reduced nephrotoxicity and ototoxicity that maintain readthrough activity have been developed (Shulman et al., 2014; Xue et al., 2014). In addition, non-aminoglycoside PTC readthrough compounds have been identified by high-throughput library screening (Du et al., 2009; Kayali et al., 2012), and some have been chemically modified to improve activity (Hamada et al., 2019; Taguchi et al., 2012, 2017). In addition, several compounds have been found to enhance the activity of PTC readthrough compounds, allowing the use of reduced doses of aminoglycosides and thus reduced toxicity (Baradaran-Heravi et al., 2016; Ferguson et al., 2019).

With these technological advances, PTC readthrough-based therapy has become a realistic option. However, whether nonsense readthrough therapy is applicable to Alport syndrome is unexplored. Here, we tested the feasibility of PTC readthrough therapy for X-linked Alport syndrome by generating a NanoLuc-based translation reporter system to evaluate which COL4A5 nonsense variants are susceptible to readthrough therapy. Forty-nine nonsense variants reported in patients with Alport syndrome were tested, and 11 of them were highly sensitive to aminoglycoside-mediated PTC readthrough. Moreover, we found that designer aminoglycoside and non-aminoglycoside PTC readthrough drugs with reduced nephrotoxicity and ototoxicity induced synthesis of full-length PTC readthrough-sensitive variants. Also, PTC readthrough enhancer compounds potentiated aminoglycoside-mediated PTC readthrough. These results contribute important basic knowledge regarding the feasibility of PTC readthrough therapy in Alport syndrome and suggest that a fraction of patients should benefit from it.

RESULTS

Development of a NanoLuc-based COL4A5 translation reporter system

The efficacy of aminoglycoside-induced PTC readthrough varies greatly from variant to variant (Lincoln et al., 2018). At least, 76 COL4A5 nonsense variants have been reported in patients with X-linked Alport syndrome, accounting for 6% of the known variants (Savige et al., 2016). Therefore, determining which nonsense variants are susceptible to PTC readthrough is a crucial first step toward clinical application. To evaluate the sensitivity of COL4A5 nonsense variants to PTC readthrough in a high-throughput system, we generated a COL4A5-NanoLuc reporter plasmid by in-frame fusion of NanoLuc to the COOH-terminus of COL4A5 (Figure 1A). Introduction of a PTC into the COL4A5-NanoLuc cDNA leads to synthesis of truncated protein without the COOH-terminal NanoLuc, so luminescence is not produced. In this reporter system, it is assumed that a small molecule compound such as an aminoglycoside will promote PTC readthrough, leading to synthesis of a full-length protein and production of luminescence.

First, we introduced a pathogenic nonsense variant, R1563X, into the COL4A5-NanoLuc cDNA to see if we could detect PTC readthrough in the presence of G418, which is known to have high readthrough activity and is considered the gold standard PTC readthrough drug in vitro. G418 increased luminescence in HEK293 cells expressing COL4A5-R1563X-NanoLuc to a level that was 20%–30% of that of WT (Figure 1B). Moreover, to show that the PTC readthrough was not artifactually related to the presence of the NanoLuc RNA sequence in the transcript, we investigated whether G418 could induce PTC readthrough of COL4A5-R1563X mRNA, using COL4A5-R1563X-DeltaNanoLuc (Figure 1C). Immunoblot analysis showed G418 induced
PTC readthrough in HEK293 cells expressing either COL4A5-R1563X-NanoLuc or COL4A5-R1563XΔNanoLuc (Figure 1D). These results show that the COL4A5-NanoLuc reporter cDNA was sensitive and quantitative enough for monitoring translation of full-length COL4A5 protein in a multi-well plate format.

Screening for PTC readthrough-susceptible COL4A5 nonsense variants

To screen COL4A5 nonsense variants reported in patients with X-linked Alport syndrome for susceptibility to PTC readthrough, we introduced 49 pathogenic variants individually into the COL4A5-NanoLuc cDNA reporter by site-directed mutagenesis. Nonsense variants in the collagenous domain that originally encoded Gly were excluded, because if the PTC readthrough product is not Gly, the Gly substitution will likely impair the function of the PTC readthrough product. Aminoglycoside-induced PTC variants are known to be influenced by the type of PTC (UGA > UAG > UAA) (Wangen and Green, 2020). Therefore, we selected all three types of nonsense variants for evaluation. Nonsense variant COL4A5-NanoLuc plasmids were...
individually transfected into HEK293 cells, and the cells were treated for 24 h with different concentrations of G418. G418 induced significant PTC readthrough of 40 of the 49 nonsense variants (Figures 2A–2C). Many of them were statistically significant, but some did not have high PTC readthrough rates. Of the types of variants that responded to G418, UGA PTCs showed the highest readthrough rates, which agrees with previous studies. 11 of 49 COL4A5 nonsense variants (C29X, S36X, E130X, C1521X, R1563X, C1567X, W1594X, S1632X, R1683X, C1684X, and K1689X) showed more than 5-fold induction of PTC readthrough.

**Figure 2. Identification of COL4A5 variants susceptible to G418-induced PTC readthrough**

(A–C) Luminescence was measured in cell lysates from HEK293 cells co-transfected with either CMV-NanoLuc-fused COL4A5-WT or the indicated nonsense variants and HSV-TK-Luc2 (firefly) for normalization. Cells expressing one UGA (A), UAG (B), or UAA (C) COL4A5 nonsense variant cDNA were treated with G418 at the indicated concentrations for 24 h, and luminescence was measured. G418 induced readthrough of some but not all PTCs. The box extends from the 25th to 75th percentiles. Data are represented as mean ± SEM.

(D) Readthrough efficiency of eleven readthrough-susceptible mutants was compared to WT. The box extends from the 25th to 75th percentiles. Data are represented as mean ± SEM. Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test (n = 4). *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.001 vs. no treatment. RLU, relative light units.
The amount of luminescence produced from these G418-susceptible variants ranged from 10%–30% of the WT level (Figure 2D).

**Gentamicin, an aminoglycoside approved for clinical use, induces PTC readthrough in G418-susceptible mutants**

Although G418 is one of the most potent readthrough inducers, it is toxic and cannot be used clinically. Gentamicin is a clinically approved aminoglycoside class antibiotic. Therefore, we investigated whether gentamicin induced PTC readthrough of the G418-susceptible mutants. COL4A5-NanoLuc reporter cDNAs with introduced nonsense variants (C29X, S36X, E130X, R1563X, C1567X, W1594X, S1632X, R1683X, C1684X, and K1689X) were transfected into HEK293 cells, and the extent of PTC readthrough induction by gentamicin treatment was quantified by measuring luminescence. Gentamicin significantly induced PTC readthrough of G418 susceptible variants except for COL4A5-K1689X (Figure 3A). The amount of full-length protein produced with gentamicin-induced readthrough peaked at 5%–10% of WT for most variants, which was 2–3 times less effective than G418 (Figure 3B). To further investigate PTC readthrough in different cell types, we examined 6 variants highly responsive to PTC readthrough using HeLa, mouse podocyte, and COS-7 cell lines. As in the experiments with HEK293 cells, wild-type and various variant plasmids were transfected into each cell line, and G418- and gentamicin-induced PTC readthrough were evaluated. Similar to HEK293 cells, both G418 and gentamicin induced PTC readthrough in the other cell types (Figures 3C and 3D).

**The efficacy of aminoglycoside-mediated PTC readthrough is dose- and treatment time-dependent**

To investigate whether aminoglycoside-induced PTC readthrough is treatment time-dependent, we performed long-term treatment experiments using low doses of aminoglycosides on cells expressing COL4A5-R1563X and -R1683X variants, which were highly responsive to G418 and gentamicin. For long-term treatment, we generated stable COL4A5-R1563X- and COL4A5-R1683X-NanoLuc cDNA-expressing cells by lentivirus transduction. The degree of PTC readthrough was increased with low-dose G418 treatment in a time-dependent manner (Figures 4A and 4B). The low concentrations of G418 (10 and 30 μg/mL) slightly increased readthrough, and the moderate concentration (100 μg/mL) dramatically increased full-length protein synthesis, depending on treatment time. The longer treatment with low concentrations of gentamicin (30 and 100 μg/mL) did not increase the efficacy of PTC readthrough, but readthrough was increased at the moderate (300 μg/mL) and high (1000 μg/mL) concentrations (Figures 4C and 4D).

**Designer aminoglycoside and non-aminoglycoside readthrough drugs induce PTC readthrough in the highly susceptible variant COL4A5-R1563X**

The potential for successful PTC readthrough therapy with aminoglycosides is dependent on their degrees of activity, nephrotoxicity, and ototoxicity (Forge and Schacht, 2000). Aminoglycoside toxicity is attributed to a structural site different from that responsible for PTC readthrough activity (Matt et al., 2012; Shulman et al., 2014). Therefore, chemical modification has been used to reduce the toxicity of aminoglycosides, with the aim of reducing toxicity while maintaining readthrough activity. Several aminoglycoside derivatives have been developed and are called designer aminoglycosides (Bidou et al., 2017). The use of PTC readthrough compounds with non-aminoglycoside structures is also a strategy to reduce toxicity. We tested a set of next-generation PTC readthrough drugs for efficacy at promoting readthrough of COL4A5-R1563X, a G418-susceptible mutant (Figure 2A). HEK293 cells expressing the COL4A5-R1563X-NanoLuc cDNA were treated with several PTC readthrough drugs for 24 h (Figure 5). Whereas G418 exhibited the highest readthrough activity (Figure 5A), ELX-02, the negamycin analog CDX008, RTC13, and 2,6-diaminopurine (DAP) significantly induced PTC readthrough dose dependently, but RTC14 and PTC124 did not (Figures 5B–5F and S1A). ELX-02 and DAP showed the highest PTC readthrough activity among them (Figures 5B and 5F). These results suggest that ELX-02, a designer aminoglycoside, and DAP, a purine derivative, have PTC readthrough activity for G418-sensitive variants such as R1563X, but they are expected to exhibit reduced toxicity.

**Designer aminoglycoside and non-aminoglycoside PTC-RT drugs are ineffective for the non-G418-susceptible variant COL4A5-G5X**

In addition to the G418-susceptible COL4A5-R1563X variant, we also tested whether any next generation PTC readthrough drugs induced PTC readthrough for the G418 non-susceptible COL4A5-G5X variant.
Figure 3. Gentamicin induces PTC readthrough of G418-susceptible COL4A5 variants

(A) Luminescence was measured in cell lysates from HEK293 cells co-transfected with either CMV-NanoLuc-fused COL4A5-WT or the indicated nonsense variants and HSV-TK-Luc2 (firefly) for normalization. COL4A5-NanoLuc expressing cells were treated with gentamicin (as indicated) for 24 h, and luminescence was measured. The box extends from the 25th to 75th percentiles. Data are represented as mean ± SEM.

(B) Readthrough efficiency of eleven susceptible mutants was compared to WT.

(C–E) Luminescence was measured in cell lysates from HeLa cells (C), mouse Podocyte cell line (mPCL) (D), and COS-7 cells (E) co-transfected as in (A). COL4A5-NanoLuc-expressing cells were treated with gentamicin (as indicated) for 24 h, and luminescence was measured. Readthrough efficiency of six susceptible mutants was compared to WT. The box extends from the 25th to 75th percentiles. Data are represented as mean ± SEM. Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test (n = 4). *, p < 0.05; ***, p < 0.005; ****, p < 0.001 vs. no treatment.

RLU, relative light units
Only ELX-02 and RTC13 significantly induced PTC readthrough of COL4A5-G5X (Figures 5B–5L and S1B). However, the extent of induction was much less than in the case of COL4A5-R1563X (Figures 5B and 5H). These results indicate that PTC readthrough was not strongly induced in the G418-non-susceptible COL4A5-G5X variant by either ELX-02, which has the same mechanism as G418, or DAP, which exerts its effects via a different mechanism.

Enhancer drugs improve the efficiency of aminoglycoside-induced PTC readthrough

Several PTC readthrough enhancer compounds have been developed to reduce aminoglycoside-induced toxicity by lowering the dose required for sufficient PTC readthrough. The PTC readthrough enhancer CDX5 was identified in a yeast cell-based assay in the presence of the aminoglycoside paromomycin. The effect of CDX5 was also significant in mammalian cells (Baradaran-Heravi et al., 2016). A more recent study showed that the antimalarial drug mefloquine potentiated G418-mediated PTC readthrough in mammalian cells (Ferguson et al., 2019). Here, we investigated whether readthrough enhancers potentiate aminoglycoside-mediated PTC readthrough in the G418-susceptible COL4A5-R1563X and non-susceptible COL4A5-G5X variants. Mefloquine and CDX5 derivatives potentiated both G418- and gentamicin-mediated PTC readthrough of COL4A5-R1563X (Figures 6A and 6B). On the other hand, only mefloquine potentiated both G418 and gentamicin-mediated PTC readthrough of COL4A5-G5X (Figures 6C and 6D). Although aminoglycoside-mediated PTC readthrough of COL4A5-G5X was enhanced by mefloquine, the induction was weaker than that for COL4A5-R1563X without enhancers.

Functionality of the possible PTC readthrough products of G418-susceptible mutants

So far, we have evaluated COL4A5 nonsense variants in terms of their susceptibility to PTC readthrough, but whether the resulting protein product is functional or not is also important for therapeutic applications. PTC readthrough drugs suppress PTC by facilitating the insertion of near-cognate aminoacyl-tRNAs into the ribosomal-A site during protein translation. Therefore, the readthrough product is often a full-length protein with an incorrect amino acid at the PTC. If such a substitution impairs the function of the protein, it may be difficult to rescue the variant phenotype even if a full-length protein is produced.
To begin to investigate whether the PTC readthrough products from G418-susceptible variants are functional, we utilized a split-NanoLuc-based collagen IV a3a4a5 heterotrimer formation assay. This platform assays a3a4a5 heterotrimer formation by measuring the luminescence produced by the proximity of NanoLuc fragments fused to the ends of COL4A3 and COL4A5 that are brought together during the formation of COL4A3/4/5 heterotrimers (Figure 7A) (Omachi et al., 2018). Most pathogenic COL4A5 missense variants affect a3a4a5 heterotrimer formation and prevent production of functional collagen IV a3a4a5, which causes Alport syndrome. Therefore, assessing whether PTC readthrough products can assemble into a3a4a5 heterotrimers is important for evaluating the feasibility of PTC readthrough therapy.

It is known that during G418-induced PTC readthrough, Arg, Trp, and Cys are inserted for UGA, Tyr and Gln are inserted for UAA, and Gln is inserted for UAA (Dabrowski et al., 2018). The potential readthrough products from G418-susceptible COL4A5 variants are shown in Table 1. In several cases, it is possible that PTC readthrough will result in production of some wild-type protein. To investigate the function of the mutant readthrough products, all possible missense mutant substitutions were generated by site-directed mutagenesis and assayed using the C-terminal tagged split NanoLuc-based a3a4a5 heterotrimer assay. The luminescence reflecting heterotrimer formation was significantly decreased intracellularly and extracellularly for some readthrough products from C1521X, R1563X, C1567X, W1594X, R1683X, and C1684X. On the other hand, all readthrough products from C29X, S36X, E130X, S1632X, and K1689X retained the ability to form a3a4a5 heterotrimers (Figures 7B and 7C). It should be noted that for Arg (R) codons mutated to UGA, more than half of the product is the wild-type R (Roy et al., 2016), so a higher percentage of functional full-length proteins are produced than for Cys (C) to UGA and Trp (W) to UGA mutants. For C29X, S36X, and E130X, the variants are located close to the N-terminus; thus, in addition to the C-terminal tag assays (Figure 7A, left), we also evaluated the function of readthrough products using the N-terminal tag system (Figure 7A, right). The extent of heterotrimer formation for C29X-derived products was reduced by half, whereas S36X- and E130X-derived products retained their functions (Figure 7D). These results indicate that inducing PTC readthrough is a valid approach for a subset of COL4A5 nonsense variants.

Aminoglycosides induced PTC readthrough of Col4a5-R1563X in primary kidney cells derived from mutant mice

Although we evaluated PTC readthrough in cell systems overexpressing mutant cDNAs, our ultimate goal is to induce PTC readthrough of nonsense mutant mRNA derived from endogenous COL4 genes. There are two strains of mouse models for Alport syndrome that carry a Col4a5 nonsense mutation: the Col4a5-G5X mouse (Rheault et al., 2004) and the Col4a5-R471X mouse (Hashikami et al., 2019). Our cell-based assay identified GSX as a non-responsive nonsense variant. Furthermore, R471X is not conserved in the human genome (human: Q471X (UAA), mouse R471X (UGA)). Therefore, we generated an Alport syndrome mouse model carrying the Col4a5-R1563X nonsense mutation, a variant susceptible to PTC readthrough in cell-based assays (Figures 1A and 2A). We designed a specific single guide (sg) RNA targeting near the codon of interest. Then, the sgRNA, Cas9 protein, and a single-stranded DNA oligonucleotide carrying the mutation were introduced into zygotes by electroporation (Figure 8A) to produce founders. Because the Col4a5-R1563X variant is located near an exon-intron junction, we assayed for splicing abnormalities by RT-PCR and Sanger sequencing using RNA from Col4a5-R1563X mice. This assay revealed no splicing abnormalities and showed that the targeted mutation was correctly inserted (Figure 8B). The absence of type IV collagen a3a4a5 in the GBM of Col4a5-R1563X mice was confirmed by immunofluorescence (Figure 8C).

To directly investigate the feasibility of bypassing an endogenous Col4a5 nonsense variant by PTC readthrough, we studied primary kidney cells from Col4a5 nonsense mutant mice. We investigated COL4A5
Figure 6. PTC readthrough enhancer drugs increase the efficiency of readthrough

Luminescence was measured in cell lysates from HEK293 cells co-transfected with CMV-NanoLuc-fused COL4A5-R1563X (A, B) or -G5X (C, D) and HSV-TK-Luc2 (firefly) for normalization. Cells were treated with the indicated doses of G418 (A, C) or gentamicin (B, D) supplemented with the indicated readthrough enhancer compounds at 20 μM, and the efficiency of readthrough was compared to WT. Mefloquine and CDX-288 enhanced the readthrough efficacy of both G418 and gentamicin in COL4A5-R1563X-expressing cells. CDX6-180 slightly enhanced gentamicin-mediated PTC readthrough of
protein expression in primary Col4a5-R1563X cells from whole kidney and from isolated glomeruli after treatment with either G418 or gentamicin for 24 h. To increase intracellular protein abundance, the cells were co-treated with the ER-Golgi transport inhibitor Brefeldin A so that COL4A5 protein would accumulate. Full-length COL4A5 protein expression was induced in Col4a5-R1563X primary kidney cells and in primary glomerular cells treated with either G418 or gentamicin (Figure 8D). Finally, we compared full-length protein production using primary kidney cultures from mice carrying Col4a5-R1563X, which is highly susceptible to PTC readthrough, vs. -G5X, which is less susceptible (Figures 1A and 2B). Consistent with our cell-based assays, we found that G418 and gentamicin induced full-length protein synthesis in R1563X cells but not in G5X cells (Figure 8E).

**DISCUSSION**

The goal of this study was to determine the applicability of PTC readthrough therapy in Alport syndrome caused by nonsense variants. Because the susceptibility to PTC readthrough differs greatly among variants (Bidou et al., 2004; Pranke et al., 2018), the first step would be to determine which variants are susceptible. Because the type IV collagen genes are relatively large with many reported nonsense variants (Crockett et al., 2010; Savige et al., 2016), we thought it is essential to evaluate a simple reporter system with high throughput to cover most of them. In addition, previous studies have shown that PTC readthrough activity is affected by the sequences surrounding the nonsense variants (Stiebler et al., 2014; Wangen and Green, 2020). Therefore, we constructed a reporter using the full-length COL4A5 cDNA instead of a short cDNA containing the PTC. Because the full-length COL4A5 cDNA itself is about 5 kb, we used NanoLuc as a reporter to construct the fusion gene because of its small size (513 bp) and high sensitivity (England et al., 2016; Hall et al., 2012). The COL4A5-NanoLuc reporter cDNA developed in this study allowed us to identify which of 49 tested COL4A5 nonsense variants are susceptible to PTC readthrough. Also, this study showed the efficacy of next generation PTC readthrough drugs and potentiator compounds that enhance PTC readthrough activity. Finally, to demonstrate proof of concept for PTC readthrough of an endogenous Col4a5 nonsense variant, we generated a Col4a5 mutant mouse line with one of the susceptible nonsense variants, Col4a5-R1563X. Ex vivo experiments with primary cells showed that aminoglycosides induced PTC readthrough of endogenous Col4a5-R1563X.

Through comprehensive variant screening, we found that UGA COL4A5 nonsense variants were more susceptible to aminoglycoside-mediated PTC readthrough than UAG and UAA. This is consistent with previous studies (Bidou et al., 2004). However, as previously reported, not all UGA PTCs showed high susceptibility (Nudelman et al., 2010), and it was reconfirmed that susceptibility varied depending on the variant. Susceptibility is known to be affected by the surrounding nucleotide sequence. To attempt to determine whether susceptibility is based on the flanking nucleotide sequence, we aligned the cDNA sequences around PTCs that were G418-susceptible and compared them to those flanking the non-susceptible PTCs (Figure S2). However, no overt differences between susceptible and non-susceptible sequences were observed. This suggests that susceptibility is defined by factors other than the peripheral sequence, such as the location of the variant in the gene. Although more detailed comparative studies are needed, these results highlight the importance of screening for PTC readthrough using full-length cDNAs rather than just short cDNA reporters carrying sequence near the PTC.

One limitation of this reporter system is that the presence of nonsense-mediated mRNA decay (NMD) cannot be taken into account because the mRNA derived from the cDNA does not need to be spliced and thus does not have the spliced exon-exon junctions that are required for mRNA surveillance (Popp and Maquat, 2014). mRNAs produced from genes with nonsense variants are partially degraded by NMD (Trcek et al., 2013). Therefore, promotion of basal readthrough by suppression of NMD is one of the therapeutic strategies for nonsense variants, but we have not been able to investigate this. However, because induction of PTC readthrough by NMD inhibition alone is not expected to be very high (Bhuvanagiri et al., 2014), and many aminoglycosides have an activity that inhibits NMD, this limitation is not likely a
serious problem, but it should be taken into account to accurately determine PTC readthrough activity in vivo. To overcome this limitation, CRISPR/Cas9-mediated genome editing could be used to create cells with point mutants in endogenous genes (Anzalone et al., 2020), which would allow the evaluation of PTC readthrough activity under the same conditions as in vivo. However, the throughput of this method would be very low, and it is not suitable for evaluating a large number of variants as in the present study.

In addition to defining the readthrough susceptibility of each variant, it is also important to determine whether the possible PTC readthrough products are functional (Brumm et al., 2012). To investigate this, we used split-NanoLuc-based type IV collagen α3445 heterotrimer formation assays to identify which G418-induced full-length but missense variant proteins are functional. Some variants had high readthrough activity but may lose function when a different amino acid from the original is inserted. Many of the variants are located in the COL4A5 C-terminal NC1 domain, which is essential for α5 to form a functional triple-helical structure with other α-chains (Sundaramoorthy et al., 2002). Therefore, structural changes in the protein due to missense variants are likely to interfere with the formation of the correct NC1 complex. However, the results showed that the wild-type S1632 and K1689 residues are not required to form the NC1 complex (Figures 8B and 8C). Also, C29 and S36 in the N-terminal 7S domain and E130 in the N-terminal collagenous domain could be replaced without total inhibition of heterotrimer assembly (Figures 8B–8E). The results suggest that C29 substitution did not impact NC1 complex formation, but partially affected assembly at the N-terminus. This is consistent with the importance of the Cys residue in the 7S domain for disulfide bond formation to other α-chains (Risteli et al., 1980). Using two different assay systems, the PTC readthrough reporter assay and the α3445 heterotrimer assay, we identified several variants that seem truly susceptible to PTC readthrough therapy.

The biggest challenge in PTC readthrough therapy is the toxicity of drugs used at high concentrations for long periods of time to induce synthesis of enough full-length proteins to impact phenotypes. Treatment with high concentrations of aminoglycosides involves the risk of nephrotoxicity and ototoxicity. Fortunately, these issues are being addressed by the development of new PTC readthrough drugs, including new aminoglycoside derivatives (Friesen et al., 2018; Shulman et al., 2014) and non-aminoglycoside compounds (Du et al., 2009; Hamada et al., 2019; Trzaska et al., 2020). Regarding this point, we showed that an aminoglycoside derivative and non-aminoglycoside PTC readthrough drugs induced PTC readthrough in the G418-susceptible COL4A5-R1563X variant (Figure 5). In addition, from the viewpoint specific to Alport syndrome, type IV collagen α3445 that incorporates into the GBM should be stable for a long period of time (Liu et al., 2020). This means that once enough type IV collagen α3445 is induced by PTC readthrough and incorporated into the GBM, continuous treatment should not be necessary, though intermittent treatments would likely be required. This suggests that Alport syndrome could be especially suitable for PTC readthrough therapy.

In summary, the present study proposes PTC readthrough as a personalized therapeutic approach for Alport syndrome based on the susceptibility of specific pathogenic nonsense variants to readthrough. Susceptible variants account for about 10% of all nonsense variants, which amounts to <1% of all variants reported in Alport syndrome. Based on the overall frequency of Alport syndrome, the number of patients who could benefit from PTC readthrough therapy is estimated to be 8963 (Table S1). The forms of Alport syndrome caused by nonsense variants, which are classified as truncating variants, are typically more severe than the non-truncating forms, which are usually caused by missense variants. Therefore, the successful development of PTC readthrough therapy would have significant benefits for patients with the most severe forms of Alport syndrome. With various innovations such as the development of designer aminoglycosides and non-aminoglycoside PTC readthrough compounds, PTC readthrough therapy has become an increasingly realistic approach. In fact, some such compounds are in clinical trials for nephropathic cystinosis (ClinicalTrials.gov Identifier: NCT04069260) and cystic fibrosis (ClinicalTrials.gov Identifier: NCT04126473, NCT02139306). The present study provides important information on PTC readthrough-susceptible COL4A5 variants, and it is hoped...
that new gene-edited mouse models of Alport syndrome carrying the analogous variants in Col4a5 will facilitate proof-of-concept PTC readthrough studies in vivo in the near future.

**Limitations of the study**

Although we attempted to do so in Table S1, it is difficult to estimate how many patients might actually benefit from PTC readthrough therapy based on the present study alone. G418 induced statistically significant PTC readthrough of 40 of the 49 nonsense variants tested (Figure 2A); 11 were induced > 5-fold, and 17 were induced 2- to 3-fold. These results are from a 24 h treatment, but the actual treatment in vivo would be longer term, so the induced protein is expected to accumulate in the GBM over time. In fact, in cell-based assays, prolonging the treatment time by 2–3 days resulted in a significant increase in PTC readthrough product (Figure 4). To determine what percent of variants are amenable to PTC readthrough therapy in a clinically meaningful way, it will be necessary to investigate what level of protein induction is required to produce a therapeutic effect in future studies using mouse models. According to the results of exon skipping therapy in a mouse model of Alport syndrome (Yamamura et al., 2020a), the induction of only a small amount of type IV collagen α3α4α5 in the GBM showed significant therapeutic effects, so

---

**Table 1. Potential PTC readthrough products from G418-susceptible mutants**

| Nonsense mutation | PTC readthrough products | Predicted ratio (Dabrowski et al., 2018) | Structural location |
|-------------------|---------------------------|------------------------------------------|--------------------|
| C29X (UGA)        | C29R                      | 64.5 ± 11.8%                             | 7S                 |
|                   | C29C (WT)                 | 17.7 ± 8.0%                              |                    |
|                   | C29W                      | 17.9 ± 6.8%                              |                    |
| S36X (UGA)        | S36R                      | 64.5 ± 11.8%                             | 7S                 |
|                   | S36C                      | 17.7 ± 8.0%                              |                    |
|                   | S36W                      | 17.9 ± 6.8%                              |                    |
| E130X (UAA)       | E130Y                     | 47.9 ± 14.1%                             | Collagenous (Gly-X-Y) |
|                   | E130Q                     | 52 ± 14.2%                               |                    |
| C1521X (UGA)      | C1521R                    | 64.5 ± 11.8%                             | NC1                |
|                   | C1521C (WT)               | 17.7 ± 8.0%                              |                    |
|                   | C1521W                    | 17.9 ± 6.8%                              |                    |
| R1563X (UGA)      | R1563R (WT)               | 64.5 ± 11.8%                             | NC1                |
|                   | R1563C                    | 17.7 ± 8.0%                              |                    |
|                   | R1563W                    | 17.9 ± 6.8%                              |                    |
| C1567X (UGA)      | C1567R                    | 64.5 ± 11.8%                             | NC1                |
|                   | C1567C (WT)               | 17.7 ± 8.0%                              |                    |
|                   | C1567W                    | 17.9 ± 6.8%                              |                    |
| W1594X (UGA)      | W1594R                    | 64.5 ± 11.8%                             | NC1                |
|                   | W1594C                    | 17.7 ± 8.0%                              |                    |
|                   | W1594W (WT)               | 17.9 ± 6.8%                              |                    |
| S1632X (UGA)      | S1632R                    | 64.5 ± 11.8%                             | NC1                |
|                   | S1632C                    | 17.7 ± 8.0%                              |                    |
|                   | S1632W                    | 17.9 ± 6.8%                              |                    |
| R1683X (UGA)      | R1683R (WT)               | 64.5 ± 11.8%                             | NC1                |
|                   | R1683C                    | 17.7 ± 8.0%                              |                    |
|                   | R1683W                    | 17.9 ± 6.8%                              |                    |
| C1684X (UGA)      | C1684R                    | 64.5 ± 11.8%                             | NC1                |
|                   | C1684C (WT)               | 17.7 ± 8.0%                              |                    |
|                   | C1684W                    | 17.9 ± 6.8%                              |                    |
| K1689X (UAA)      | K1689Y                    | 0.8 ± 7.0%                               | NC1                |
|                   | K1689Q                    | 8.6 ± 8.3%                               |                    |

---

*OPEN ACCESS*
Figure 8. Ex vivo experiments with Col4a5-R1563X mice shows PTC readthrough of an endogenous nonsense variant

(A) Schematic diagram showing gRNA and ssODN targeting sites to generate the Col4a5-R1563X mutant via CRISPR/Cas9.

(B) Schematic diagram shows the R1563X codon (TGA) split between exons 50 and 51. The gel image shows RT-PCR products amplified from exon 49 to 52 from WT and Col4a5-R1563X kidney RNA. No splicing abnormalities were detected. Sanger sequencing shows the desired R1563X nonsense mutation.

(C) Immunofluorescence staining for COL4A5 protein shows its absence from Col4a5-R1563X mouse kidney. Scale bar: 100 µm.

(D) Immunoblot images of COL4A5 protein shows PTC readthrough of the endogenous Col4a5-R1563X. G418 and gentamicin induced full-length protein expression (*) in Col4a5-R1563X primary kidney cells (left) and glomerular cells (right).

(E) Comparison of PTC readthrough efficiency between Col4a5-R1563X and -G5X primary kidney cells. G418 and gentamicin induced PTC readthrough in R1563X cells but not in G5X cells. This is consistent with cell-based PTC readthrough experiments. Statistical analysis was performed using two-way ANOVA with Dunnett’s multiple comparisons test (n = 3). *, p < 0.05; **, p < 0.01; vs. no G418 or gentamicin treatment.
perhaps even low rates of PTC readthrough may, over time, have therapeutic effects. Further studies are clearly necessary before this therapy can be translated into clinical practice, both in terms of readthrough efficiency and toxicity of long-term treatment.

STAR+ METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell culture and cell lines
  - Mouse models
- METHODS DETAILS
  - Chemical compounds
  - Plasmids
  - Transfection, lentivirus production, infection and treatment
  - Cell lysis, gel electrophoresis, and immunoblotting
  - Luciferase assay
  - Immunofluorescence
  - Ex-vivo experiments with primary kidney cells
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.103891.

ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of Health (R01DK078314 and R01DK128660 to J.H.M.), the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital (MI-II-2019-796 to J.H.M. and CORE-2019-820 to the Pediatric Disease Mouse Models Core), the Japan Society for the Promotion of Science (JSPS) (JP19H03379 to H.K.), the JSPS Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (S2803 to H.K.), and the JSPS Program for Postdoctoral Fellowships for Research Abroad (to K.O.). We thank Yoav Segal for the Col4a5-G5X mice, David Powell of Chinook Therapeutics for synthesis and validation of ELX-02 and CDX-008, Jennifer Richardson for genotyping, the Genome Engineering and iPSC Center (GEiC) at Washington University for CRISPR reagent validation services, and the Mouse Genetics Core at Washington University for producing gene-edited mice and for mouse husbandry. We also thank the Alport Syndrome Foundation for encouragement to pursue these studies.

AUTHOR CONTRIBUTIONS
K.O. designed the research, conducted experiments, and wrote the manuscript. J.H.M., H.K., and M.R. designed the research and edited the manuscript. All authors discussed the results and provided input on the manuscript.

DECLARATION OF INTERESTS
H.K. holds a patent related to this work, Japanese Patent Application No. 2017-99497. J.H.M. receives research support from Chinook Therapeutics, Lung Therapeutics, Inc., Myonid Therapeutics, and the Alport Syndrome Foundation. The other authors report no conflicts of interest.

Received: July 25, 2021
Revised: December 22, 2021
Accepted: February 4, 2022
Published: March 18, 2022
premature termination codon readthrough of premature termination codons. Mol. Med. 24, 25. https://doi.org/10.1186/s12890-018-0224-7.

Du, L., Damoiseaux, R., Nahas, S., Gao, K., Hu, H., Pollard, J.M., Goldstine, J., Jung, M.E., Henning, S.M., Bertoni, C., and Gatti, R.A. (2009). Nonaminoglycoside compounds induce readthrough of nonsense mutations. J. Exp. Med. 206, 2285–2297. https://doi.org/10.1088/jem.20091940.

Du, M., Keeling, K.M., Fan, L., Liu, X., Kovacs, T., Sorscher, E., and Bedwell, D.M. (2006). Clinical doses of ampicillin provide more effective suppression of the human CFTF-GS42X stop mutation than genticin in a transgenic CF mouse model. J. Mol. Med. (Berlin) 84, 573–582. https://doi.org/10.1002/jm.20045-5.

England, C.G., Ehlerding, E.B., and Cai, W. (2016). NanoLuc: a small luciferase is brightening up the field of bioanalysis. J. Biotechnol. 227, 1175–1187. https://doi.org/10.1016/j.jbiotec.2016.11.012.

Ferguson, M.W., Gerak, C.A.N., Chow, C.C.T., Rastelli, E.J., Elmore, K.E., Stahl, F., Hosseini-Farahabadi, S., Baradan-Heravi, A., Colart, D.M., and Roberge, M. (2019). The antimarial drug mefloquine enhances TP53 premature termination codon readthrough by aminoglycoside G418. PLoS ONE 14, e0216423. https://doi.org/10.1371/journal.pone.0216423.

Forge, A., and Schacht, J. (2000). Aminoglycoside antibiotics. Audiol. Neurootol. 5, 3–22. https://doi.org/10.1159/000013861.

Friesen, W.J., Johnson, B., Sienna, J., Zhuo, J., Vazirani, P., Xue, X., Tomizawa, Y., Baiazitov, R., Morrill, C., Ren, H., et al. (2018). The minor gentamicin complex component, X2, is a potent premature termination codon readthrough molecule with therapeutic potential. PLoS ONE 13, e0206158. https://doi.org/10.1371/journal.pone.0206158.

Gross, O., Birowski, B., Koepeik, M.L., Kuck, J., Reiner, M., Addicks, K., Smyth, N., Schulze-Lohoff, E., and Weber, M. (2003). Premptive ramiplir therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 63, 438–446. https://doi.org/10.1046/j.1523-1755.2003.00779.x.

Gross, O., Tonshoff, B., Weber, L.T., Pape, L., Latta, K., Fehrenbach, H., Lange-Sperandio, B., Zappel, H., Hoyer, P., Staude, H., et al. (2020). A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport syndrome. Kidney Int. 97, 1275–1286. https://doi.org/10.1016/j.kint.2019.12.015.

Gunwar, S., Ballester, F., Noeckel, M.E., Sado, Y., Ninomiya, Y., and Hudson, B.G. (1999). Glomerular basement membrane. Identification of a novel disulphide-cross-linked network of alpha3, alpha4 and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J. Biol. Chem. 274, 8767–8775. https://doi.org/10.1074/jbc.273.15.8767.

Hall, M.P., Unch, J., Binkowski, B.F., Valley, M.P., Butler, B.L., Wood, M.G., Otto, P., Zimmerman, K., Vidugiris, G., Machleidt, T., et al. (2012). Engineered luciferase reporter from a deep sea shrimp utilizing a novelimidazoazepinone substrate. ACS Chem. Biol. 7, 1848–1857. https://doi.org/10.1021/cb3002478.

Hamada, K., Omura, N., Taguchi, A., Baradan-Heravi, A., Koteake, M., Arai, M., Takayama, K., Taniguchi, A., Roberge, M., and Hayashi, Y. (2019). New negamycin-based potent readthrough derivative effective against TGA-type nonsense mutations. ACS Med. Chem. Lett. 10, 1450–1456. https://doi.org/10.1021/acsmedchemlett.9b00273.
promote nonsense suppression. Proc. Natl. Acad. Sci. U S A 113, 12508–12513. https://doi.org/10.1073/pnas.1605336113.

Roy, B., Leszyk, J.D., Mangus, D.A., and Jacobson, A. (2015). Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3. Proc. Natl. Acad. Sci. U S A 112, 3038–3043. https://doi.org/10.1073/pnas.1412477112.

Savage, J., Storey, H., Il Cheong, H., Gyu Kang, H., Park, E., Hilbert, P., Persikov, A., Torres-Fernandez, D., Ans, E., Trottier, R., et al. (2016). X-linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype-phenotype correlations. PLoS One 11, e0161802. https://doi.org/10.1371/journal.pone.0161802.

Schwiik, D., Endlich, N., Holzman, L., Holthofer, H., Kuz, W., and Hudson, B.G. (2002). Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes. J. Biol. Chem. 277, 31420–31425. https://doi.org/10.1074/jbc.M201402000.

Taguchi, A., Hamada, K., Shiozuka, M., Kobayashi, M., Murakami, S., Takayama, K., Taniguchi, A., Usui, T., Matsuda, R., and Hayashi, Y. (2017). Structure-activity relationship study of leucyl-3-epi-deoxynegamycin for potent premature termination codon readthrough. ACS Med. Chem. Lett. 8, 1060–1065. https://doi.org/10.1021ACSmedchemlett.7b00269.

Taguchi, A., Nishiguchi, S., Shiozuka, M., Nomoto, T., Ina, M., Nojima, S., Matsuda, R., Nonomura, Y., Kusó, Y., and Yamaizumi, Y. (2012). Negamycin analogue with readthrough-promoting activity as a potential drug candidate for duchenne muscular dystrophy. ACS Med. Chem. Lett. 3, 118–122. https://doi.org/10.1021/ml200245t.

Trcek, T., Sato, H., Singer, R.H., and Maquat, L.E. (2013). Temporal and spatial characterization of nonsense-mediated mRNA decay. Genes Dev. 27, 541–551. https://doi.org/10.1101/gad.209635.112.

Tyszka, C., Amand, S., Bailly, C., Leroy, C., Marchand, V., Duvernois-Berthet, E., Salou, J.M., Benhabiles, H., Werkmeister, E., Chassat, T., et al. (2020). 2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations. Nat. Commun. 11, 1509. https://doi.org/10.1038/s41467-020-15140-z.

Wangen, J.R., and Green, R. (2020). Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides. Elife 9. https://doi.org/10.7554/eLife.52611.

Wilson, H.M., and Stewart, K.N. (2012). Glomerular epithelial and mesangial cell culture and characterization. Methods Mol. Biol. 806, 187–201. https://doi.org/10.1007/978-1-61779-367-7_13.

Woodley, D.T., Cogan, J., Hou, Y., Lyu, C., Marinkovich, M.P., Keene, D., and Chen, M. (2017). Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J. Clin. Invest 127, 3028–3038. https://doi.org/10.1172/JCI92707.

Xue, X., Mutym, V., Tang, L., Biswas, S., Du, M., Jackson, L.A., Dai, Y., Belakov, V., Shalev, M., Chen, F., et al. (2014). Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am. J. Respir. Cell Mol. Biol. 50, 805–816. https://doi.org/10.1165/rcmb.2013-0282OC.

Yamamura, T., Horinouchi, T., Adachi, T., Terakawa, M., Takaoka, Y., Omichi, K., Takeda, M., Takashiba, K., Shoji, T., Onishi, Y., et al. (2002a). Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5. Nat. Commun. 3, 2777. https://doi.org/10.1038/ncomms4160.

Yamamura, T., Horinouchi, T., Nagano, C., Omori, T., Sakakibara, N., Aoto, Y., Ishiko, S., Nakashiki, K., Shima, Y., Nagase, H., et al. (2002b). Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int. 98, 1605–1614. https://doi.org/10.1016/j.kint.2020.06.038.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Rat IgG anti-COL4A5 NC1 monoclonal antibody (clone H52) | Chondrex | Cat# 7077 |
| Rat IgG anti-COL4A5 NC1 monoclonal antibody (clone H53) | Chondrex | Cat# 7078 |
| Mouse IgG1 anti-Vinculin monoclonal antibody (clone 7F9) | Santa Cruz | Cat# sc-73614; RRID:AB_1131294 |
| Rabbit IgG anti-Laminin-111 polyclonal antibody | Sigma-Aldrich | Cat# L9393; RRID:AB_477163 |
| Goat IgG anti-Rat IgG secondary antibody, Alexa 488 | Invitrogen | Cat# A-11006; RRID:AB_2534074 |
| Goat IgG anti-Rabbit IgG secondary antibody, Alexa 594 | Invitrogen | Cat# A-11012; RRID:AB_141359 |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| G418 disulfate solution (50 mg/mL) | Sigma-Aldrich | Cat# G8168 |
| RTC13 | Sigma-Aldrich | Cat# SML1725 |
| 2,6-Diaminopurine (DAP) | Sigma-Aldrich | Cat# 247847 |
| Brefeldin A | Sigma-Aldrich | Cat# B6542 |
| Gentamicin (50 mg / mL) | Life Technologies | Cat# 15750-060 |
| ELX-02 | Sussex Research | N/A |
| Negamycin analog CDX008 | WuXi AppTec | N/A |
| RTC14 | ChemBridge | Cat# 5311257 |
| PTC124 | Cayman Chemical | Cat# 16758 |
| Lipofectamine 3000 Transfection Reagent | Invitrogen | Cat# L3000001 |
| FuGENE® 6 Transfection Reagent | Promega | Cat# E2691 |
| X-tremeGENE™ 360 Transfection Reagent | Roche | Cat# XTG360-RO |
| **Critical commercial assays** |        |            |
| Nano-Glo® Dual-Luciferase Reporter Assay System | Promega | Cat# N1620 |
| SuperSignal West Pico Chemiluminescent Substrate | Thermo Scientific | Cat# 34580 |
| Amersham ECL select Western Blotting Detection Reagent | Cytiva | Cat# RPN2235 |
| Pierce BCA Protein Assay Kit | Thermo Scientific | Cat# 23225 |
| **Experimental models: Cell lines** |        |            |
| Human: HEK293 cells | ATCC | Cat# CRL-1573; RRID: CVCL_0045 |
| Human: 293T cells | ATCC | Cat# CRL-3216; RRID: CVCL_0063 |
| Human: HeLa cells | ATCC | Cat# CCL-2; RRID: CVCL_0030 |
| Mouse: podocyte cells | Schweck et al., 2004 | N/A |
| Monkey: COS-7 cells | ATCC | Cat# CRL-1651; RRID: CVCL_0224 |
| **Experimental models: Organisms/strains** |        |            |
| Mouse: Col4a5<tm1Yseg>/<GSX> | The Jackson Laboratory | Cat# 006183; RRID:MGi:3610502 |
| Mouse: Col4a5<R1563X> | This study | N/A |
| **Oligonucleotides** |        |            |
| sgRNA for R1563X production, see STAR Methods | This study | N/A |
| ssODN for R1563X production, see STAR Methods | This study | N/A |
| Primers for the site-directed mutagenesis, see Table S1 | This study | N/A |
| Primers for splicing analysis in Col4a5-R1563X mouse, see STAR Methods | This study | N/A |
| Primers for Sanger sequencing see STAR Methods | This study | N/A |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Recombinant DNA     |        |            |
| pNLF1-C             | Promega| Cat# N1361 |
| pGL4.54 [luc2/TK]   | Promega| Cat# E5061 |
| pNLF1-C-COL4A5-Nluc: WT | This study | N/A |
| pNLF1-C-COL4A5-Nluc: G5X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: C29X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Y30X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: S36X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: E130X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q182X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: E228X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: R226X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: E287X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: E291X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: E305X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Y320X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: R373X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q379X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q407X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: K408X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q471X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q580X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: L755X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q928X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q930X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: E989X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1016X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1052X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1061X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: S1071X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: K1097X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1180X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1234X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: K1320X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1383X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1499X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Q1501X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: C1521X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Y1543X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: W1538X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: R1563X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: C1567X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: E1574X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: W1594X | This study | N/A |
| pNLF1-C-COL4A5-Nluc: Y1597X | This study | N/A |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| pNL1-C-COL4A5-Nluc: S1632X | This study | N/A |
| pNL1-C-COL4A5-Nluc: S1661X | This study | N/A |
| pNL1-C-COL4A5-Nluc: R1674X | This study | N/A |
| pNL1-C-COL4A5-Nluc: C1684X | This study | N/A |
| pNL1-C-COL4A5-Nluc: Q1685X | This study | N/A |
| pNL1-C-COL4A5-Nluc: K1689X | This study | N/A |
| pLV SIN-Puro Human COL4A5-Nluc: WT | This study | N/A |
| pLV SIN-Puro Human COL4A5-Nluc: R1563X | This study | N/A |
| pLV SIN-Hygro Luc2 | This study | N/A |
| pFC36K SmBiT TK-Neo Human COL4A3 | Omachi et al., 2018 | N/A |
| pLV SIN-Puro Human COL4A4 | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: WT | Omachi et al., 2018 | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: G869R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C29R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C29W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: S36R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: S36C | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: S36W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: E130Q | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C1521R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C1521W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: R1563C | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: R1563W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C1567R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C1567W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: W1594R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: W1594C | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: S1632R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: S1632C | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: S1632W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: R1683C | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: R1683W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C1684R | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: C1684W | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: K1689Y | This study | N/A |
| pFC34K LgBiT TK-Neo Human COL4A5: K1689Q | This study | N/A |
| pFN35K SmBiT TK-Neo Human COL4A3 | Omachi et al., 2018 | N/A |
| pFN33K LgBiT TK-Neo Human COL4A5: WT | Omachi et al., 2018 | N/A |
| pFN33K LgBiT TK-Neo Human COL4A5: C29R | This study | N/A |
| pFN33K LgBiT TK-Neo Human COL4A5: C29W | This study | N/A |
| pFN33K LgBiT TK-Neo Human COL4A5: S36R | This study | N/A |
| pFN33K LgBiT TK-Neo Human COL4A5: S36C | This study | N/A |
| pFN33K LgBiT TK-Neo Human COL4A5: S36W | This study | N/A |
| pFN33K LgBiT TK-Neo Human COL4A5: E130Q | This study | N/A |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to the lead contact, Dr. Jeffrey H. Miner (minerj@wustl.edu).

Materials availability
Reagents generated in this study are available from the lead contact under Material Transfer Agreements.

Data and code availability
- This paper does not contain any datasets and codes.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell culture and cell lines
Human embryonic kidney (HEK) 293 cells (ATCC CRL-1573), 293T cells (ATCC CRL-3216) and COS-7 cells (CRL-1651) were maintained at 37 °C, 5% CO₂ in Dulbecco’s Modified Eagle's Medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum and penicillin-streptomycin. HeLa cells (ATCC-CCL-2) were maintained at 37 °C, 5% CO₂ in Minimum Essential Medium supplemented with 10% heat inactivated fetal bovine serum and penicillin-streptomycin. The mouse podocyte cell line (mPCL) (Schiwek et al., 2004) was maintained at 33 °C, 5% CO₂ in RPMI-1640 supplemented with 10% heat inactivated fetal bovine serum, penicillin-streptomycin and recombinant interferon-γ (100U / mL). For PTC readthrough experiments, HEK293, HeLa, mPCL and COS-7 cells were used. We did not use 293T cells for PTC readthrough experiments because 293T cells are G418-resistant. For function tests of the potential PTC readthrough products by split NanoLuc assay, 293T cells were used. Cells stably expressing cDNAs were generated by lentivirus infection. Transduced cells were selected by culturing in DMEM with appropriate antibiotics for 2 weeks.

Mouse models
To generate Col4a5-R1563X mice, a single guide RNA (5’-CAGCCATTCATTAGTCCGTA-3’) targeting the 3’ end of Col4a5 exon 50, a single-stranded DNA oligonucleotide with the R1563X mutation (5’-GCTTCAA GAAATGACTATCTTACTGCTTTCACCCAGAGCCATGCAATGGAACCCCTGAAGGGACAGACATCCAGCCATTCATTAGTGGTAAAGGCACTGGTTAGCTTGCATTTAACATTACC CCCCTT AGTTTAGCTAGTAAGAAATCAGTGAATCCATGATACTCACCACCCAAGTT-3’), and Cas9 protein were introduced into FVB/NJ zygotes by electroporation. Mutations in the founder mice were analyzed by deep sequencing after genomic amplification with primers (5’-TCGATTCAACATGGCAGGCTGCTG-3’, 5’-GTAGCACTTGGCTAACTAGGTGATGCATCCC-3’). The RNA splicing pattern and mRNA sequence were analyzed by RT-PCR with RNA isolated from male Col4a5WT/Y and Col4a5R1563X/Y kidney tissues. The primer sequences were: sense, 5’- aacagaagcaccacaatgcccacgg-3’; anti-sense, 5’- gcccatgagcatcc-3’. The splicing pattern between Exons 49 and 52 was determined by agarose gel electrophoresis and by Sanger sequencing. FVB/NJ Col4a5-R1563X mice were backcrossed to C57BL/6J mice for 2 weeks.
at least four generations. Col4a5-G5X mutant mice (Col4a5<sup>tm1Yseg</sup>, JAX: 006183) were obtained from Yoav Segal. RT-PCR analysis of kidney RNA showed that this mutation does not impact RNA splicing (Figure S3). All animal experiments conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Washington University Animal Studies Committee.

METHODS DETAILS

Chemical compounds

G418 disulfate solution (50 mg/mL), RTC13, 2,6-diaminopurine, and Brefeldin A were purchased from Sigma-Aldrich (catalog no. G8168, SML1725, 247847 and B6542). Gentamicin (50 mg / mL) was purchased from Gibco, Life Technologies Corporation (catalog no. 15750-060). ELX-02 was synthesized by Sussex Research. The negamycin analog CDX008 (Figure S1) was synthesized by WuXi AppTec. RTC14 was from ChemBridge Corporation (catalog no. 5311257). PTC124 was purchased from Cayman Chemical (catalog no. 16758).

Plasmids

To generate the COL4A5 with C-terminal NanoLuc fusion expression vector, full-length human COL4A5 cDNA was amplified from pEF6-COL4A5-Myc (Omachi et al., 2018), cloned into pNLF1-C [CMV/Hygro] vector (Promega). pLV-BSD COL4A5-LgBiT (C terminal tag), pLV-Hygro COL4A3-SmBiT (C terminal tag), pLV-Puro COL4A4, pFN33K-COL4A5-LgBiT (N terminal tag) and pFN35K-COL4A3-SmBiT (N terminal tag) were used for split NanoLuc luciferase-based COL4A3/4/5 trimer formation assay (Omachi et al., 2018). For all luciferase assays, pGL4.54 [luc2/TK] (Promega) was used as a co-transfected control vector. The variant COL4A5 expression vectors used in this study were generated by site-directed mutagenesis as previously described. Primer sequences are shown in Table S2. The introduced variants were verified by Sanger sequencing.

Transfection, lentivirus production, infection and treatment

HEK293, HeLa and COS-7 cells were transfected with pNLF1-C-COL4A5-Nluc (WT and mutants) and pGL4.54 [luc2/TK] plasmids by FuGENE 6 transfection reagent (Promega). mPCL were transfected with pNLF1-C-COL4A5-Nluc (WT and mutants) and pGL4.54 [luc2/TK] plasmids by X-treamGENE 360 transfection reagent (Roche). Formation of plasmids/FuGENE 6 or X-treamGENE 360 complexes was performed according to the manufacturer’s instructions. At 48 h after transfection, cells were treated with DMEM containing G418 or other PTC readthrough drugs.

To produce lentivirus, 293T packaging cells were seeded at 5.5-6.0 \times 10^5 cells per well in DMEM in 6-well tissue culture plates. Seeded cells were incubated at 37 \degree C, 5% CO\textsubscript{2} for \sim 20 h. Culture media were changed to fresh DMEM with 10% heat inactivated fetal bovine serum and transfected with 1\mu g of psPAX2 (Addgene: #12260), 100 ng of pMD2.G (Addgene: #12259), and 1\mu g of lentivirus transfer vector per well by Lipofectamine 3000 transfection reagent (Invitrogen) according to the manufacturer’s instructions. 24 h after transfection, culture media were changed to DMEM supplemented with 30% heat inactivated fetal bovine serum. Lentivirus-containing supernatants were collected after 24 h and filtered with 0.45 \mu m PVDF or PES membrane syringe filter unit. HEK293 cells or 293T cells were seeded in filtered lentivirus containing media supplemented with 8 \mu g/mL polybrene (Sigma) and cultured for 24 h, then cells were cultured in DMEM with 10% FBS and the appropriate antibiotics for 2 weeks (Hygromycin; 200-400 \mu g/mL, Blasticidin; 10 \mu g/mL, Puromycin 10 \mu g/mL).

Cell lysis, gel electrophoresis, and immunoblotting

Transfected HEK293 cells were washed twice with ice-cold phosphate buffered 0.9% saline (PBS) and lysed in RIPA buffer (0.05 M Tris-HCl [pH 7.5], 0.15 M NaCl, 1% v/v Nonidet P-40, 1% w/v Na deoxycholate, and 1% protease inhibitor cocktail). The cell lysates were centrifuged at 14,000 g for 15 min at 4 \degree C, and clear supernatants were collected. The protein concentration was determined using a bicinchoninic acid kit (Thermo), and equal amounts of protein lysates were loaded and separated by SDS PAGE, immunoblotted with anti-COL4A5 NC1 antibody (HS2, Chondrex) for human COL4A5 cDNA-transfected HEK293 cells, anti-COL4A5 NC1 antibody (HS3, Chondrex) for mouse primary cells, and anti-vinculin antibody (7F9, Santa Cruz), and visualized using Super-Signal West Pico Chemiluminescent Substrate (Thermo) and ECL select Western Blotting Detection Reagent (Cytiva).
Luciferase assay

pNLF1-C-COL4A5-NanoLuc and HSV-TK-Luc2 plasmids were transfected into HEK293, HeLa, mPCL and COS-7 cells. After 48 h, cells were fed with culture media containing the test compounds. At 72 h after transfection, Nano-Glo Dual Luciferase Reporter Assay reagent (Promega) was added, and the luciferase activity in the cell lysates was measured using a GloMax Navigator system (Promega). All luciferase assays were conducted in LumiNunc 96-well white plates (Invitrogen). NanoLuc luciferase was normalized by constitutively expressed firefly luciferase.

Immunofluorescence

Kidneys were harvested from anesthetized 1-month-old male Col4a5WT/Y and Col4a5R1563X/Y mice, and unfixed kidneys were immersed in O.C.T. compound (Tissue-Tek, Sakura Finetek) in a Cryomold (Tissue-Tek, Sakura Finetek) and frozen in liquid nitrogen. Unfixed 7μm frozen sections were blocked with 1% bovine serum albumin/PBS at room temperature for 1 h. Then, sections were incubated with rat IgG anti-COL4A5 antibody (HS3, 1/200) and rabbit IgG anti-laminin-111 antibody (Sigma L9393, 1/200) at room temperature for 2 h. Next, sections were washed with PBS three times and incubated with secondary antibodies; Alexa 488-anti-Rat-IgG antibody (1/200) and Alexa 594-anti-Rabbit-IgG antibody (1/200) in PBS containing 1% normal mouse serum at room temperature for 30 min. Sections were washed three times with PBS, mounted, and observed under a fluorescence microscope.

Ex-vivo experiments with primary kidney cells

Kidneys were removed from anesthetized 1-month-old male Col4a5WT/Y, Col4a5G5X/Y, Col4a5R1563X/Y, and female Col4a5WT/Y, Col4a5G5X/G5X, Col4a5R1563X/R1563X mice perfused with PBS. The kidneys were minced to 1-2 mm² pieces on ice and digested in 1 mg/mL collagenase and 100U/mL DNase I for 30 min at 37°C. After digestion, they were filtered with a 100μm cell strainer and then centrifuged (200 g, 5 min). The supernatants were removed, and tissue pellets were dissociated with PBS. They were filtered with a 100μm cell strainer and then centrifuged (200 g, 5 min) again. The supernatants were removed and tissue pellets were dissociated with cell culture media. Cell suspensions were seeded onto type I collagen coated tissue culture dishes. Attached cells were maintained at 37°C, 5% CO2 in RPMI-1640 supplemented with 10% heat inactivated fetal bovine serum and penicillin-streptomycin, insulin, transferrin, and selenium. After 3 days culture, cells were dissociated with 0.25% trypsin/EDTA and filtered with a 30μm cell strainer and then centrifuged (200 g, 5 min). Cell pellets were dissociated with culture media and seeded onto type I collagen coated dishes and used for experiments.

Primary glomerular cells were isolated by a mesh sieving method (Wilson and Stewart, 2012). The kidneys were removed and minced into 1-2 mm² pieces on ice. The minced kidneys were filtered with 250 μm and 100 μm cell strainers. The filtered tissue suspension was passed through a 75 μm filter, after which the remaining glomeruli on the mesh were isolated. Isolated glomeruli were cultured on type I collagen-coated dishes. Cells were maintained at 37°C, 5% CO2 in RPMI-1640 supplemented with 10% heat inactivated fetal bovine serum and penicillin-streptomycin, insulin, transferrin, and selenium. After 6 days culture, cells were dissociated with 0.25% trypsin/EDTA and filtered with a 30μm cell strainer and then centrifuged (200 g, 5 min). Cell pellets were dissociated with culture media and seeded onto type I collagen coated dishes and used for experiments. Intracellular proteins were extracted with RIPA buffer (0.05 M Tris-HCl [pH 7.5], 0.15 M NaCl, 1% v/v Nonidet P-40, 1% w/v Na deoxycholate, and 1% protease inhibitor cocktail). mRNA was extracted with TRizol Reagent (Invitrogen) according to the manufacturer’s instructions.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical parameters are reported in the Fig. Legends. Immunoblot experiments were performed in triplicate using 3 independent transfections. Luciferase assays were performed in quadruplicate using 4 independent cell cultures. The significance of differences between two groups was assessed using Student’s unpaired two-tailed t-tests. For three-group comparisons, we used analysis of variance (ANOVA) with Turkey-Kramer post-hoc or Dunnett’s tests. Differences with p values of less than 0.05 were considered statistically significant.